Eli Lilly and Coverage Initiated by Analysts at Deutsche Bank (LLY)
Analysts at Deutsche Bank assumed coverage on shares of Eli Lilly and (NYSE:LLY) in a research report issued to clients and investors on Wednesday, TheFlyOnTheWall.com reports. The firm set a “buy” rating on the stock.
Several other analysts have also recently commented on the stock. Analysts at Jefferies Group cut their price target on shares of Eli Lilly and from $65.00 to $61.00 in a research note on Monday, August 11th. They now have a “hold” rating on the stock. Separately, analysts at S&P Equity Research initiated coverage on shares of Eli Lilly and in a research note on Friday, August 1st. They set a “buy” rating on the stock. Finally, analysts at Morgan Stanley raised their price target on shares of Eli Lilly and from $48.00 to $60.00 in a research note on Friday, August 1st. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and eleven have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $63.86.
Eli Lilly and (NYSE:LLY) opened at 62.81 on Wednesday. Eli Lilly and has a 52 week low of $47.53 and a 52 week high of $65.70. The stock has a 50-day moving average of $62.24 and a 200-day moving average of $59.89. The company has a market cap of $67.313 billion and a P/E ratio of 19.92.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Thursday, July 24th. The company reported $0.68 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.65 by $0.03. The company had revenue of $4.94 billion for the quarter, compared to the consensus estimate of $4.88 billion. During the same quarter in the prior year, the company posted $1.16 earnings per share. The company’s quarterly revenue was down 16.8% on a year-over-year basis. Analysts expect that Eli Lilly and will post $2.78 EPS for the current fiscal year.
Eli Lilly and Company, discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products.
Receive News & Ratings for Eli Lilly and Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co and related companies with Analyst Ratings Network's FREE daily email newsletter.